Pulmonary Arterial Hypertension
GB002 Inc. focuses its clinical research on pulmonary arterial hypertension, with studies centered on WHO Group 1 pulmonary hypertension and the management of disease burden in patients receiving background PAH therapy.
- Exercise capacity
- Long-term safety
- Tolerability
The sponsor’s trial portfolio reflects sustained interest in inhaled treatment approaches for PAH, including ongoing evaluation of treatment durability and clinical benefit in a multi-country research network.
Inhaled Therapy for Cardiopulmonary Disease
The company’s research activity is concentrated on orally inhaled treatment strategies for cardiopulmonary disease, with attention to therapies designed for chronic use in patients with pulmonary vascular disorders.
- Oral inhalation
- Chronic treatment maintenance
- Adjunctive disease-specific medication
Current studies examine how inhaled therapy can be integrated with established PAH treatment regimens across active research sites in multiple countries.
Safety and Tolerability Research
A major area of interest for GB002 Inc. is the assessment of long-term safety and tolerability in people treated for pulmonary arterial hypertension, with continued follow-up of inhaled therapy in routine clinical contexts.
- Long-term exposure
- Safety monitoring
- Treatment persistence
These studies support ongoing evaluation of treatment suitability for patients requiring prolonged management of PAH.
